Details of the Drug

General Information of Drug (ID: DMM1Z9G)

Drug Name

Vutrisiran

Synonyms

ALN-TTRsc02

Indication

Disease Entry	ICD 11	Status	REF
Hereditary amyloidosis	5D00.2	Approved	[1]
Transthyretin familial amyloid cardiomyopathy	5D00.20	Phase 3	[2]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

N07XX18: Vutrisiran

N07XX: Other nervous system drugs

N07X: OTHER NERVOUS SYSTEM DRUGS

N07: OTHER NERVOUS SYSTEM DRUGS

N: NERVOUS SYSTEM

Drug Type

Small interfering RNA

Sequence

>Subunit 1
UGGGAUUUCAUGUAACCAAGAX
>Subunit 2
UCUUGGUUACAUGAAAUCCCAUC

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin messenger RNA (TTR mRNA)	TTPOYU7	TTHY_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215515.
2	ClinicalTrials.gov (NCT03759379) HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.